Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ebos GroupASX:EBO +0.74%79 Forward PE Ratio is 15.71 as of Jul. 18, 2026. GuruFocus rates ASX:EBO with a GF Score™ of 79/100 and a GF Value™ of A$31.56 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 51 Medical Distribution companies, Ebos Group ranks worse than 52.94% on this metric.
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Ebos Group Forward PE Ratio Related Terms
Ebos Group Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Ebos Group's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ebos Group Forward PE Ratio Chart
Ebos Group Annual Data
Trend
2016-06
2017-06
2018-06
2019-06
2020-06
2021-06
2022-06
2023-06
2024-06
2025-06
Forward PE Ratio
16.95
17.76
16.21
20.88
18.38
24.57
25.38
23.75
21.46
21.62
Ebos Group Semi-Annual Data
2015-12
2016-06
2016-12
2017-06
2017-12
2018-06
2018-12
2019-06
2019-12
2020-06
2020-12
2021-06
2021-12
2022-06
2022-12
2023-06
2023-12
2024-06
2024-12
2025-06
2025-12
Forward PE Ratio
17.01
16.95
17.36
17.76
17.70
16.21
18.90
20.88
23.20
18.38
24.88
24.57
32.47
25.38
29.50
23.75
22.47
21.46
24.56
21.62
18.77
ASX:EBO vs MCK, CAH, COR: Forward PE Ratio Comparison
For the Medical Distribution subindustry, Ebos Group's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group Forward PE Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Ebos Group's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Ebos Group (ASX:EBO) has a Forward PE Ratio of 15.71 as of Jul. 18, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Ebos Group and its competitors. According to the industry distribution chart, Ebos Group ranks #27 out of 51 companies in the Medical Distribution industry, placing it in the top 52.9%.
Is Ebos Group's Forward PE Ratio too high?
Ebos Group's current Forward PE Ratio is 15.71. The Medical Distribution industry median Forward PE Ratio is 14.75. Ebos Group's value of 15.71 is 6.5% above this industry median. Based on the distribution chart, Ebos Group ranks #27 out of 51 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Ebos Group has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's Forward PE Ratio compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #27 out of 51 companies for Forward PE Ratio. This places Ebos Group in the lower half of its industry. The industry median Forward PE Ratio is 14.75. Ebos Group's value of 15.71 is 6.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Distribution company?
The median Forward PE Ratio among Medical Distribution companies is 14.75, based on 51 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ebos Group's current Forward PE Ratio of 15.71 is 6.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Ebos Group and its competitors. For the Medical Distribution industry, the median Forward PE Ratio is 14.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current Forward PE Ratio is 15.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Based on GuruFocus' analysis, Ebos Group (ASX:EBO) is currently considered Significantly Undervalued. The stock's GF Value™ is A$31.56, compared to a current price of A$18.99 — trading 39.8% below its estimated fair value. The current Forward PE Ratio is 15.71 and 6.5% above the Medical Distribution industry median of 14.75. Ebos Group's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Ebos Group (ASX:EBO), the current Forward PE Ratio is 15.71 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (ASX:EBO) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of A$18.99 is trading 39.8% below its estimated GF Value™ of A$31.56.
GuruFocus considers Ebos Group to be Significantly Undervalued.
Key valuation signals for ASX:EBO:
Forward PE Ratio: 15.71
GF Value™: A$31.56 vs. price of A$18.99 (39.8% below fair value)
Industry Position: 6.5% above the Medical Distribution median (#27 of 51)
No single metric tells the full story. See the ASX:EBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
79GF Score
Get the complete analysis for ASX:EBO
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EBO has been successfully added to your 
